Asia FX muted, dollar weakens slightly ahead of Fed rate decision
On Tuesday, Canaccord Genuity adjusted its price target for Arcturus Therapeutics (NASDAQ:ARCT) stock, bringing it down to $66 from the previous $68, while still upholding a Buy rating on the shares. Currently trading at $11.59, the stock appears undervalued according to InvestingPro analysis, with analyst targets ranging from $44 to $140. The firm’s analyst highlighted the latest earnings report for the first quarter of 2025 as providing additional insights since their recent meetings with the company’s management.
Arcturus’ cystic fibrosis (CF) program remains a central point of interest, with data readouts now anticipated in mid-2025, a slight shift from the previously expected second quarter of 2025. The upcoming data announcement is set to include safety and FEV1 data from approximately 6 to 9 patients across two dosage cohorts, with interim data points between day 0 and day 28. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 5.64, though it’s currently burning through cash rapidly.
Additionally, the company has signaled that updates on its Ornithine Transcarbamylase (OTC) deficiency program are expected in the second quarter of 2025. This update will include key biomarker assessments, such as glutamate levels and ureagenesis measured by the 15N assay, from the Phase 2 trial.
In a strategic move, Arcturus has reallocated resources, diminishing efforts on early-stage vaccine development to prioritize the CF and OTC programs. However, projects related to the H5N1 and seasonal influenza vaccines continue to progress.
The analyst reiterated the Buy rating following the revision of financial estimates for the first quarter of 2025. The rating reflects continued confidence in the company’s pipeline and its strategic focus on advancing its CF and OTC programs. For deeper insights into Arcturus Therapeutics’ financial health, growth prospects, and comprehensive analysis, access the full InvestingPro Research Report, which includes over 30 key metrics and expert analysis available exclusively to subscribers.
In other recent news, Arcturus Therapeutics reported its first-quarter 2025 financial results, revealing a significant revenue shortfall and a net loss that missed analyst expectations. The company reported earnings per share at a loss of $0.52, contrasting sharply with the forecasted profit of $3.59. Revenue was reported at $29.4 million, which fell short of the anticipated $205.21 million. Despite these financial challenges, the company extended its cash runway to the first quarter of 2028, focusing on advancing its mRNA therapeutics pipeline, particularly for cystic fibrosis and OTC deficiency.
Citi has maintained its Buy rating on Arcturus Therapeutics with a $44.00 price target, following the company’s decision to halt certain early-stage vaccine programs. This strategic move allows Arcturus to concentrate on its OTC deficiency and cystic fibrosis treatments, which Citi analysts view as having potential for significant impact. The firm has also placed Arcturus on a 90-day Upside Catalyst Watch, anticipating positive developments in the company’s clinical pipeline.
Arcturus has made a strategic decision to focus resources on its mRNA therapeutics pipeline, with key trials expected to yield results in the second and third quarters of 2025. The company is also working towards regulatory milestones for its COVID-19 vaccine program, with a Marketing Authorization Application filing in the UK and a U.S. BLA filing anticipated later in 2025. These developments reflect Arcturus’s ongoing efforts to address unmet medical needs and potentially enhance its valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.